JP2006335725A - Composition for improving bloodstream - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a composition for improving bloodstream having excellent bloodstream-improving effect and further having high safety and practicality and being widely useable for beverages and foods, feed, quasi-drugs, medicines, etc., therefore. <P>SOLUTION: The composition for improving bloodstream comprises at least one selected from a group consisting of elaeocarpusin, chebulagic acid, geraniin and corilagin as an active ingredient. These ingredients are derived from natural plants having actual results taken in human bodies over a long period, e.g, amla and are free from fear inducing strong adverse action even if they are taken in large amounts and have high safety. Therefore, the composition has high practicality and can widely be used for beverages and foods, feed, quasi-drugs, medicines, etc. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to a composition for improving blood flow comprising, as an active ingredient, at least one selected from the group consisting of elaeocarpusin, chebulagic acid, geraniin and corilagin. And foods and drinks, feeds, quasi-drugs, and pharmaceuticals containing the same.

  In recent years, aging, westernization of eating habits, lack of exercise, excessive stress, etc. are major causes of increasing cardiovascular diseases such as arteriosclerosis and cerebral infarction. In such circulatory system diseases, a decrease in blood flow in microvessels has been observed, and it has been pointed out in recent years that this may have various adverse effects on living bodies. Further, in familiar places, the relationship between itching of the skin, fatigue, high blood pressure and the like and blood flow has been pointed out.

  In the human body, blood circulation plays an important role in supplying oxygen and nutrients, and removing carbon dioxide and other metabolic waste products. These two functions are indispensable for the activity and survival of tissue cells. In addition, biological defense functions and immune functions are functions that depend on this blood circulation. Thus, blood circulation is involved in many important biological functions. It has long been recognized that healthy blood circulation is essential for human health. There have also been many reports on the effects of food taken with daily meals on the heart and vascular system.

  As described above, a great deal of attention has been directed to the effects of food on blood circulation and the heart / vascular system, while the importance of blood fluidity has often been overlooked. The reason for this is that, firstly, blood is a “liquid” and it has been assumed that it has “high fluidity”. Second, it is difficult to measure blood fluidity unexpectedly. It was difficult. However, plasma, the “liquid” component of blood, is only about half of the blood component (volume), and the other half is cellular components (red blood cells, white blood cells, platelets; red blood cells mostly). Considering this, it is understood that blood is not always fluid.

  This blood fluidity loses balance due to various factors such as smoking, hypertension, hyperlipidemia, and diabetes. When the symptom progresses, a significant peripheral blood circulation disorder occurs and the tissue becomes abnormal. This also makes it easy to understand that maintaining blood fluidity is essential for health.

  The fact that blood whose half volume is a cellular component can move as if it is “liquid-like” is due to blood viscosity, leukocyte deformability and adhesion, platelet adhesion, and red blood cell deformability. In particular, it is largely due to the deformability of red blood cells. The definition of erythrocyte deformability is not necessarily unified, but it is understood that it is the resistance to erythrocyte shape change, or the mechanical adaptation that erythrocytes exhibit to take on new forms (blood rheology). Recent progress, Medical Review, Inc., 14-56, 1992).

  The effect of red blood cell deformability on blood fluidity is more directly important when the blood vessel is a capillary vessel. The diameter of the capillary is about 5 μm on average, although it varies depending on the tissue. On the other hand, the diameter of red blood cells (biconcave disk) is about 8 μm for humans. Therefore, it is clear that erythrocytes cannot pass through capillaries unless they are deformed. Therefore, the deformability of erythrocytes is the most important factor that affects the blood flow velocity or blood flow of capillaries, and it can be said that it is the basic mechanism of blood fluidity.

  Attention is now being focused on the mechanism by which red blood cell deformability is maintained and how it is affected by environmental factors such as diet. Therefore, ingestion of foods and food ingredients that have an effect of improving blood flow is considered to be effective in preventing blood flow reduction, which is considered to be one of the causes of various diseases including cardiovascular diseases. It is thought that it can contribute to prevention and health promotion. In addition, many foods and food ingredients that have the potential to improve blood flow have been reported so far, and specific examples thereof include umeboshi, plum extract (see, for example, Patent Document 1), black vinegar ( For example, refer to Patent Document 1) and Tartary soba.

JP-A-11-228561

  By the way, even if a food or a food component that can be expected to have an improvement in blood flow is found, it cannot be widely applied to foods and the like if there is a problem in flavor or properties. Therefore, from the viewpoint of practicality, it is desirable that the flavor, properties, etc. have few difficulties. Furthermore, from the viewpoint of safety, it is desirable that there is no risk of inducing strong side effects even if a large amount is ingested.

  The present invention has been made in view of the above problems, and its purpose is to have excellent blood flow improvement effect, and because of its high safety and practicality, food and drink, feed, quasi drug, An object of the present invention is to provide a composition for improving blood flow that can be widely used in medicines and the like. Another object of the present invention is to provide a food / beverage product, a feed, a quasi-drug, and a pharmaceutical product containing the excellent blood flow improving composition.

  Therefore, the inventors of the present application have studied and studied from various viewpoints for the purpose of searching for blood flow improving components among various substances, and as a result, have excellent blood flow improving effects on elaeocalpsin, keblagic acid, geraniin and corilagin. I discovered something new. Accordingly, the inventors of the present application have further developed this new knowledge and completed the following invention.

  That is, the gist of the present invention is a composition for improving blood flow, characterized in that it contains at least one selected from the group consisting of elaeocalpsin, keblagic acid, geraniin and corilagin as an active ingredient. . Since this composition has an excellent effect of improving the fluidity of blood, it is possible to prevent the occurrence of blood circulation disorders and the coagulation of blood. Moreover, this composition is derived from a natural plant that has been ingested by humans over a long period of time, and even if it is ingested in large quantities, there is no risk of inducing strong side effects and it is highly safe. Therefore, the composition is highly practical and can be widely used in foods and drinks, feeds, quasi drugs, pharmaceuticals, and the like.

  The gist of the present invention is that the above-mentioned elaeocalpsin, keblagic acid, geraniin and corilagin are extracted from natural plants.

  Furthermore, the gist thereof includes foods and drinks, feeds, quasi-drugs, and pharmaceuticals characterized by containing the composition for improving blood flow.

  The “blood flow improvement effect” in the composition for improving blood flow of the present invention can be evaluated, for example, by a technique using a blood vessel model as described below. That is, the composition for improving blood flow of the present invention is added to the collected blood, and this is used as test blood. On the other hand, the additive-free blood is used as control blood.

  These two kinds of blood are flowed at a difference of 20 cm in water column using MC-FAN (both manufactured by Hitachi Haramachi Electronics Co., Ltd.) in Bloody 6-7, which is a finely processed flow path of a blood vessel model. And, the time for each blood to pass through the flow path is obtained as a blood flow passage time, and the blood flow improvement can be evaluated by comparing the blood flow passage time of the test blood and the blood flow passage time of the control blood. it can. In this comparison, if the blood flow passage time of the test blood is shorter than the blood flow passage time of the control blood, it can be determined that blood flow improvement has been observed.

  In addition, by setting a test in which a substance that induces thrombus, such as lipopolysaccharide, is added to the test blood and the target blood, and measuring these, the blood flow improving effect on the substance that worsens the blood flow is evaluated. be able to.

  Alternatively, blood flow improvement can be evaluated by determining and comparing the speed (blood flow speed) at which each blood passes through the flow path. In this comparison, if the blood flow velocity of the test blood is higher than the blood flow velocity of the control blood, it can be determined that blood flow improvement has been observed.

  Therefore, according to the present invention, in addition to having an excellent blood flow improvement effect, the composition for improving blood flow can be widely used for food and drink, feed, quasi-drugs, pharmaceuticals and the like because of its high safety and practicality. Things can be provided.

  Moreover, food / beverage products, feed, quasi-drugs, and pharmaceuticals containing the excellent composition for improving blood flow can be provided. For this reason, by improving the blood flow, it becomes possible to alleviate, ameliorate, or prevent the blood circulation disorder, and furthermore, it is possible to alleviate, ameliorate, or prevent the cardiovascular disease caused by the blood circulation disorder.

  Hereinafter, the composition for improving blood flow according to one embodiment of the present invention, and foods and drinks, feeds, quasi drugs, and pharmaceuticals containing the same will be described in detail.

  All of the elaeocarpsin, keblagic acid, geraniin and corilagin used in the composition for improving blood flow of the present invention can be chemically synthesized, but are substances contained in natural plants and have been ingested by humans over a long period of time. Those extracted from natural plants with a proven track record have been preferred from the viewpoint of safety.

  The origin of Elaeocarpusin is not particularly limited, but Amler (Scientific name: Phyllanthus embilica, Euphorbiaceae), Megusurinoki (Scientific name: Acer nicoense Maximowicz, moss) It is known that any plant can be used as an extraction raw material.

  The origin of chebulagic acid is not particularly limited, but it may be contained in plants such as Amler (scientific name: Phyllanthus embilica) and Momotana (scientific name: Terminaria catappa). Any plant can be used as an extraction raw material.

  The origin of geraniin is not particularly limited, but Amler (scientific name: Phyllanthus embilica, Euphorbiaceae), Akamegasiwa (scientific name: Mallatus japonica, eusaceae) Family) and Gennoshouko (scientific name: Geranium nepalense var. Thumbergii, Owlaceae) and the like, and any plant can be used as an extraction raw material.

  The origin of corilagin is not particularly limited, but Amler (scientific name: Phyllanthus embilica, Euphorbiaceae), Momotamana (scientific name: Terminaria catappa), walrus (scientific name: aphtos (scientific name: athc) It is known to be contained in plants such as Azalea), and any plant can be used as an extraction raw material.

  The natural plant used for the extraction raw material of the composition for improving blood flow of the present invention is not particularly limited as long as it is a plant containing the compound as described above, but Amler containing all the components is preferable.

  Amler is a deciduous sub-tree that belongs to the genus Euphorbiaceae, and is distributed from India to the Malaysian region and southern China, and India is considered the origin. In addition, Amler has a unique name for each region or language, for example, citrus, oil sweets, satsuma mushrooms, embrick milobaran, armaraki, malach tree, malaka tree, indian gooseberry, aronra, amira. , Amiraki, Amira Cattra, Nerikai, Neruri, Tasha, Kayuraka, Kemuraka, Nakhon Pong and others.

  Although it has been known that elaeocalpsin, keblagic acid, geraniin and corilagin exist in the above plants, there has never been a specific report regarding the fact that they have an effect of improving blood flow, and the present inventor has earnestly This is a new finding at the end of the research.

  In order to extract and prepare the compound from natural plants, conventional means used for separation and purification of natural polyphenols containing glycosides are appropriately employed. Common means include, for example, extraction, concentration, filtration, liquid separation, fractional precipitation, crystallization, honey, vacuum drying, freeze drying, adsorption chromatography, reverse phase chromatography, hydrophobic chromatography, gel filtration chromatography. , Ion exchange chromatography, thin layer chromatography and the like. Fractions obtained by fractionating the source extract of the compound by an appropriate method selected from the conventional methods as described above are selected and combined, and if necessary, further appropriate methods are used. By repeating the operations of fractionation, selection and combination, the compound purified to a desired level can be obtained. The compound thus obtained can be used in the form of a composition by mixing with other appropriate components, if necessary, and can be used in an appropriate degree of purification and form depending on the purpose. A preparation of the compound may be used.

  In the extraction of the compound from a natural plant, it is preferable to use an enzyme treatment together. By this treatment, the yield and flavor can be improved, and a component having a high blood flow improving effect can be obtained. The enzyme treatment may be performed before extraction or at the time of extraction. The pH at which the enzyme treatment is performed can be appropriately set using the optimum pH and pH stability of the enzyme used as an index. Also, the temperature at which the enzyme treatment is performed can be appropriately set using the optimum temperature and temperature stability of the enzyme to be used as an index.

  The enzyme used for the enzyme treatment of the present invention is not particularly limited, but is preferably a hydrolase frequently used in the food industry. This is because this type of enzyme has been used and is preferable from the viewpoint of safety and the like. Specific examples of the enzyme include hydrolytic enzymes such as pectinase, amylase, protease, lipase, tannase, dextranase, cellulase, hemicellulase, trypsin, and papain. Among these, it is preferable to use one type selected from pectinase, protease, tannase and cellulase, or to use two or more types in combination. According to this, the extraction efficiency can be further improved.

  Extracts and fractions from plants can be used as they are, but they can also be used after being dried and powdered by means such as spray drying or freeze drying, if necessary.

  The composition for improving blood flow in the present invention can be used for the purpose of alleviating, improving or preventing blood circulation disorders. Examples of symptoms or diseases related to the blood circulation disorder include Raynaud's phenomenon, Raynaud's disease, Raynaud's syndrome, itching of the skin, fatigue, malaise, hyperlipidemia, arteriosclerosis, myocardial infarction, cerebral infarction, hyperemia, congestion. , Bleeding, anemia, dark redness around the skin, mucous membranes, nails, lips, eyes, etc., itchy skin, bleeding tendency, easy bruising, dizziness, hot flashes, bloody blood (nosebleed), hemoptysis, vomiting, melena, Examples thereof include hematuria, muscle pain, nausea, gastric sensation, and blood flow disorder observed in insomnia. It has been clarified that blood flow reduction is observed in the symptoms or diseases listed here, and a desired effect can be expected by improving the blood flow with the composition for improving blood flow of the present invention. Specific examples of fatigue include stiff shoulders and low back pain, and also includes coldness as one aspect thereof.

  The composition for improving blood flow of the present invention can be widely applied to foods and drinks, feeds, quasi-drugs, pharmaceuticals, and the like, but is particularly preferably applied to foods and drinks that can be easily consumed by humans.

  The food / beverage products in the present invention are not particularly limited as long as they can be taken orally, such as solutions, suspensions, powders, solid moldings and the like. Specific examples of food and drink include, for example, instant noodles, retort foods, canned foods, microwave foods, instant soups and miso soups, freeze-dried foods, soft drinks, fruit juice drinks, vegetable drinks, soy milk drinks, coffee Beverages, tea beverages, powdered beverages, beverages such as concentrated beverages, nutritional beverages, alcoholic beverages, bread products such as bread, pasta, noodles, cake mixes, fried flour, bread crumbs, rice cakes, caramel, chewing gum, chocolate, cookies, Seasonings such as biscuits, cakes, pie, snacks, crackers, Japanese confectionery, dessert confectionery, sauces, tomato processed seasonings, flavor seasonings, cooking mixes, sauces, dressings, soups, curry stew , Processed fats and oils, butter, margarine, mayonnaise and other fats, milk beverages, yogurts, lactic acid bacteria beverages, ice cream Milk products, creams and other dairy products, frozen foods, processed fish products such as fish ham and sausages, fish paste products, livestock processed products such as livestock ham and sausages, canned agricultural products, jams and marmalades, pickles, boiled beans, cereals And other processed agricultural products, nutritional foods, tablets, capsules and the like.

  The intake amount of the composition for improving blood flow of the present invention as a food or drink should be adjusted according to the disease state of the present invention, the body weight, age, constitution, physical condition, etc. of the sick person. The composition for improvement can be appropriately set in the range of 10 mg to 10 g, preferably 40 mg to 5 g. The above-mentioned food and drink can be taken in one to several times a day depending on the state of illness or food.

  In the present invention, various nutritional components can be strengthened when processed into a composition for improving blood flow or a food or drink containing the composition.

Nutritional ingredients that can be enhanced include vitamins such as vitamin A, vitamin B ₁ , vitamin B ₂ , vitamin B ₆ , vitamin B ₁₂ , vitamin C, vitamin D, vitamin E, niacin (nicotinic acid), pantothenic acid, folic acid, Essential amino acids such as lysine, threonine, tryptophan, minerals such as calcium, magnesium, iron, zinc, copper, and, for example, α-linolenic acid, EPA, DHA, evening primrose oil, octacosanol, casein phosphopeptide (CPP) , Casein calcium peptide (CCP), water-soluble dietary fiber, insoluble dietary fiber, substances that contribute to human health such as oligosaccharides, and other useful substances approved as foods and food additives The above can be used.

  The feed in the present invention refers to food for feeding to organisms other than humans, and the form thereof is not particularly limited. The organism to which the feed can be applied is not particularly limited, and examples thereof include farm animals and pet animals. Examples of farmed animals include domestic animals such as horses, cows, bras, sheep, goats, camels and llamas, laboratory animals such as mice, rats, guinea pigs and rabbits, and poultry such as chickens, ducks, turkeys and ostriches. is there. Examples of pet animals include dogs and cats.

  The quasi-drugs and pharmaceuticals in the present invention refer to those prepared as oral preparations or injections according to conventional methods using excipients and other additives suitable for oral or parenteral administration. Preferred quasi-drug and pharmaceutical embodiments are oral formulations, most preferred are oral solid formulations. This is because oral solid preparations can be easily taken and are convenient to store and carry.

  Examples of oral solid preparations include tablets, powders, fine granules, granules, capsules, pills, sustained release agents and the like. The oral solid preparation of the present invention comprises an appropriate pharmacologically acceptable carrier, excipient (eg starch, lactose, sucrose, calcium carbonate, calcium phosphate etc.), binder (eg starch, gum arabic, carboxymethylcellulose, Hydroxypropyl cellulose, crystalline cellulose, alginic acid, gelatin, polyvinyl pyrrolidone, etc.), lubricants (eg, stearic acid, magnesium stearate, calcium stearate), disintegrating agents (eg, carboxymethylcellulose, talc, etc.) It is obtained by mixing with a composition and solidifying.

  In addition, oral liquid preparations include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs, etc., and generally used inert diluents such as purified water, The thing containing ethyl alcohol. The oral liquid preparation of the present invention further contains adjuvants such as wetting agents and suspending agents, sweeteners, flavors, fragrances, preservatives and the like in addition to the blood flow improving composition and diluent. May be.

  Injections suitable for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, emulsions and the like. Examples of the aqueous solution and suspension diluent include distilled water for injection and physiological saline. Examples of diluents for water-insoluble solutions and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethyl alcohol, polysorbate 80, and the like. The injection may further contain adjuvants such as preservatives, wetting agents, emulsifiers, dispersants, stabilizers (for example, lactose), and solubilizing agents (for example, glutamic acid and aspartic acid). These are sterilized, for example, by filtration through a bacteria storage filter, blending with a bactericide or irradiation. These can also be used by producing a sterile solid composition and dissolving it in sterile water or a sterile solvent for injection before use.

  The dosage of the composition for improving blood flow of the present invention as a pharmaceutical is appropriately determined according to individual cases in consideration of the administration route, disease symptoms, age of the administration subject, sex, etc. The active ingredient per person is about 10 mg / day to 10 g / day, preferably 40 mg / day to 5 g / day.

  EXAMPLES Hereinafter, although an Example demonstrates this invention in detail, a following example does not limit the scope of the present invention.

[Test Example 1] Confirmation of blood flow improvement effect 1
Here, in order to confirm the blood flow improvement effect of the composition for improving blood flow of the present invention, the change in blood flow velocity (μL / sec) when the composition for improving blood flow was added to human blood was investigated. .

  Using a vacuum blood collection tube (manufactured by Terumo Corp .: treated with heparin sodium), blood was collected from the mesenteric vein of a healthy subject in a sitting position at rest. 1 mL of the obtained blood (test blood) was dispensed, and 4 μL each of a solution prepared by adding elaeocalpsin, keblagic acid, geraniin and corilagin with a physiological saline solvent to a final concentration of 0.1 μg / mL In addition, it used for the measurement. On the other hand, as a control blood (control), a solution to which 4 μL of physiological saline as a solvent was added was prepared and subjected to measurement in the same manner.

  In addition, a test group in which 4 μg / mL of lipopolysaccharide (hereinafter referred to as LPS) that induces thrombus was added to the test blood and a test group in which the same amount of LPS was added to the control blood were set, and these were also measured. It was used for.

  The blood flow velocity was measured using MC-FAN (manufactured by Hitachi Haramachi Electronics Co., Ltd.). In addition, as a microfabricated flow path of a blood vessel model for allowing blood to pass, 8736 parallel grooves forming a fine groove having a flow path depth of 4.5 μm, a flow path width of 7 μm at the center of the depth, and a flow path length of 30 μm. A silicon single crystal substrate on which a microchannel array is arranged (Bloody 6-7; manufactured by Hitachi Haramachi Electronics Co., Ltd.) was used. And 100 microliters of blood was poured by 20 cm water column difference, and the whole blood passage time was measured as blood flow passage time. At the same time, the state of blood flow was recorded with a microscope-video camera system. As the measurement values, the average value of all three measurements was used. The obtained blood flow passage time was corrected by setting the time required for 100 μL of physiological saline to pass through to 12 seconds. Based on this correction value, the blood flow velocity (μL / second) was obtained by calculation. The results are shown in Table 1.

  In the control to which no elaeocalpsin, which is a composition for improving blood flow of the present invention, was added, the blood flow velocity was 1.55 μL / second, whereas in the test group to which ellaeocalpsin of the present invention was added, The blood flow rate was 2.53 μL / sec. In other words, since the blood flow velocity was increased by the addition of the elaeocalpsin of the present invention, the existence of a blood flow improvement effect was demonstrated. Moreover, in the two test groups to which LPS for inducing thrombus was added, the blood flow velocity was slower than that of the control. However, in the test group to which the composition A for improving blood flow of the present invention was added, the blood flow velocity was about 10 times faster than in the test group that was not. This means that the elaeocalpsin of the present invention has an effect of improving blood flow in a state where thrombi are easily formed. By the way, the same results were obtained when the same test was performed using keblagic acid, geraniin, and corilagin.

[Example 1] Preparation of composition for improving blood flow The dried Amler fruit was crushed and sieved to 40 mesh or less, 2 L of distilled water was added to 80 g of the powder, and extraction was performed at 55 ° C for 3 hours. Thereafter, the extract was centrifuged (3000 rpm, 10 minutes), the supernatant was filtered, and the extract and the residue were separated. Distilled water (2 L) was added to the residue, extraction was repeated once more under the same conditions, and the extracts were combined and then lyophilized to obtain 35.0 g of Amler extract powder.

  Acetone extract obtained by adding 60% acetone to the obtained Amler extract powder and performing extraction at 25 ° C. for 3 hours was subjected to column chromatography such as Toyopearl HW-40, MCL gel CHP 20P, Sephadex LH-20, Chromatorex ODS and the like. To obtain blood flow improving compositions A, B, C and D of the present invention.

  The obtained compositions A, B, C, and D were examined according to conventional methods such as NMR, GC-MS, and IR spectrum, and as a result, each of them contained elaeocalpsin, keblagic acid, geraniin, and corilagin as main components. found. Moreover, the content was 95%, 96%, 96%, and 94%, respectively.

[Test Example 2] Confirmation of blood flow improvement effect 2
In order to confirm the blood flow improvement effect of the compositions A to D for improving blood flow of the present invention obtained in Example 1, the measurement was performed in the same manner as in Test Example 1.

  Table 2 shows the results obtained by measuring the blood flow improving compositions A to D of the present invention obtained in Example 1 with distilled water and adjusting to 0.1 μg / mL as samples. It was.

  In the control in which the composition A for improving blood flow (Eraeocarpsin) of the present invention was not added, the blood flow velocity was 1.55 μL / second, whereas the composition A for improving blood flow of the present invention (Era In the test group to which eocalpsin was added, the blood flow velocity was 2.43 μL / sec. In other words, the blood flow velocity was increased by the addition of the composition A for improving blood flow (Eraeocalpsin) of the present invention, and thus the existence of a blood flow improving effect was demonstrated. Moreover, in the two test groups to which LPS for inducing thrombus was added, the blood flow velocity was slower than that of the control. However, in the test group to which the composition A for improving blood flow of the present invention was added, the blood flow velocity was about 10 times faster than in the test group that was not. This means that the composition A for improving blood flow (Eraeocalpsin) of the present invention has an effect of improving blood flow in a state where thrombi are easily formed. By the way, when the same test was performed using the composition B for blood flow improvement (Keblagic acid), C (geraniin), and D (collagen), the same result was obtained.

[Test Example 3] Confirmation of blood flow improvement effect 3
Furthermore, in order to confirm the blood flow improvement effect of the composition for improving blood flow of the present invention at a low concentration, the concentration of the composition for improving blood flow is changed to similarly change the blood flow velocity (μL / second). investigated.

  The test was conducted in the same manner as in Test Example 2, except that the final concentration of the blood flow improving composition of Example 1 added to the test blood was 20 ng / mL, 40 ng / mL, and 100 ng / mL. The results are shown in Table 3.

  In the control to which the composition A for improving blood flow of the present invention was not added, the blood flow velocity was 1.58 μL / second, whereas in the test group to which the composition A for improving blood flow of the present invention was added, The flow rates were 1.85 μL / sec, 2.12 μL / sec, and 2.41 μL / sec, respectively. That is, the addition of the composition A for improving blood flow according to the present invention increases the blood flow velocity in a concentration-dependent manner, demonstrating the existence of a blood flow improving effect. Similarly, the addition of the blood flow improving compositions B to D of the present invention increased the blood flow velocity in a concentration-dependent manner, and demonstrated the existence of a blood flow improving effect.

[Example 2] Preparation of food containing composition for improving blood flow (tablet confectionery) Composition A for improving blood flow obtained in Example 1, 0.5 g, lactose 30 g, DHA-containing powdered oil (Suncoat DY- 5; manufactured by Taiyo Kagaku Co., Ltd.) 12 g, sucrose fatty acid ester 4 g, and yoghurt flavor 4 g were mixed, and this mixture was pressure-molded using a rotary tableting machine to improve the blood flow of the present invention with one tablet of 300 mg. Composition-containing food or drink (tablet confectionery) was obtained. Furthermore, a blood flow improving composition-containing food or drink (tablet) was obtained in the same manner except that the blood flow improving compositions B to D were used instead of the blood flow improving composition A. In addition, as a comparative example for this, a food or drink (tablet cake) containing other components such as lactose was obtained by the same method, while not containing only the composition for improving blood flow.

  And about these 5 types of tablet confectionery, as a result of having conducted the sensory test by five panelists, the difference in any of a color, an odor, and taste was not recognized. In addition, when these two types of tablet confectionery were stored at room temperature for a long time (1 month, 3 months, 6 months), no noticeable changes in color, odor and taste were observed, and none of them was preserved. It was excellent.

[Example 3] Preparation of beverage containing composition for improving blood flow Composition A for improving blood flow obtained in Example 1, 0.5 g, 2.1 g of 1/5 concentrated grapefruit transparent fruit juice, 30 g of erythritol, citric acid Crystals 2.5 g, trisodium citrate 0.5 g, L-ascorbic acid 0.5 g, calcium lactate 1.93 g, CCP 0.15 g, and grapefruit flavor 1.0 were mixed and dissolved in water to make a total volume of 1000 mL. After filling it into a 100 mL bottle and sealing with a cap, it was sterilized by heating at 90 ° C. for 30 minutes to obtain a food / beverage product (beverage) containing the composition for improving blood flow of the present invention. Furthermore, the composition-containing food / beverage product (beverage) for improving blood flow was obtained in the same manner except that the blood flow improving compositions B to D were used instead of the blood flow improving composition A. Moreover, as a comparative example against this, food and drink (beverages) containing other components were obtained by the same method, while not containing only the composition for improving blood flow.

  And about these 5 types of drinks, as a result of having performed the sensory test by five panelists, the difference in any of a color, an odor, and taste was not recognized. In addition, when these two types of beverages were stored in a refrigerator for a long period (1 month, 3 months, 6 months), no noticeable changes in color, smell and taste were observed, and all of them were preserved. It was excellent.

[Example 4] Preparation of beverage containing composition for improving blood flow (vegetable juice mixed drink) Composition A for improving blood flow obtained in Example 1, 0.05 g, guar gum decomposition product (Sunfiber R; Taiyo Kagaku) 3 g) was added to, mixed and dissolved in 100 mL of a commercially available vegetable fruit juice mixed drink to obtain a composition-containing food or drink (vegetable fruit juice mixed drink) for improving blood flow of the present invention. Furthermore, the composition-containing food and drink for improving blood flow (vegetable juice mixed drink) was obtained in the same manner except that the blood flow improving compositions B to D were used instead of the blood flow improving composition A. Moreover, the food / beverage products (vegetable juice mixed drink) which do not contain the composition for blood flow improvement but contain a guar gum decomposition product as a comparative example with respect to this were obtained by the same method.

  And as a result of having conducted the sensory test by five panelists about these 5 types of vegetable juice mixed drinks, the difference in any of a color, an odor, and taste was not recognized. Moreover, when these five kinds of beverages were stored in a refrigerator for one month, no noticeable changes were observed in color, smell and taste, and all of them were excellent in storage stability.

[Example 5] Preparation of a composition-containing cookie for improving blood flow After putting 0.4 g of the composition A for improving blood flow obtained in Example 1 and 200 g of commercially available cake mix powder into a container, 35 g of butter was added. And mixed with a wooden cocoon. 25g of beaten egg was added to it and kneaded well until it became a smooth dough. The dough is taken out on a table on which the flour has been shaken, and further, the flour is shaken and stretched to a thickness of 5 mm with a rolling pin, extracted in a round shape, and baked in an oven at 170 ° C. for 10 minutes. A cookie containing a composition for improving blood flow was obtained. Furthermore, a composition-containing cookie for improving blood flow was obtained in the same manner except that the compositions B to D for improving blood flow were used instead of the composition A for improving blood flow.

[Example 6] Preparation of yogurt containing composition for improving blood flow, 0.1 g of composition A for improving blood flow obtained in Example 1, 95 g of commercially available skim milk (manufactured by Meiji Dairies, protein content 34%) And 35 g of commercially available unsalted butter (manufactured by Snow Brand Milk Products Co., Ltd.) was dissolved in 0.8 L of warm water, homogenized, and the total amount was adjusted to 1 L. Next, this was heat sterilized at 90 ° C. for 15 minutes, cooled, and inoculated with 3 g of commercially available lactic acid bacteria starter (manufactured by Hansen) (2 g of Streptococcus thermophilus and 1 g of Lactobacillus bulgaricus). Furthermore, after mixing this uniformly, dispensing and filling into a 100 mL container, sealing, fermenting at 37 ° C. for 20 hours, and then cooling to obtain the yogurt containing the composition for improving blood flow of the present invention. Obtained. Furthermore, instead of the composition A for improving blood flow, a yogurt containing a composition for improving blood flow was obtained in the same manner except that the compositions B to D for improving blood flow were used.

[Example 7] Preparation of oral liquid food containing composition for improving blood flow 50 g of sodium caseinate (manufactured by DMV), 42.5 g of egg white enzyme degradation product (manufactured by Taiyo Kagaku), and 100 g of dextrin (manufactured by Matsutani Chemical) Dissolved in 1 L, the aqueous phase was prepared in a tank. Separately, 45 g of MCT (manufactured by Kao Corporation), 17.5 g of palm oil (manufactured by Fuji Oil Co., Ltd.), 35 g of safflower oil (manufactured by Taiyo Oil & Fats Co., Ltd.), 0.7 g of lecithin (manufactured by Taiyo Kagaku Co., Ltd.), defoaming 1 g of an agent (manufactured by Taiyo Chemical Co., Ltd.) was mixed and dissolved to prepare an oil phase. The oil phase was added to the aqueous phase in the tank, stirred and mixed, then heated to 70 ° C., and further homogenized with a homogenizer at a pressure of 14.7 MPa. Next, the mixture was sterilized at 90 ° C. for 10 minutes, then concentrated and spray-dried to prepare about 260 g of an intermediate product powder. 200 g of this intermediate product powder, 0.4 g of the composition A for improving blood flow obtained in Example 1, 159 g of dextrin (manufactured by Matsutani Chemical Co., Ltd.), 18 g of guar gum decomposition product (Sunfiber R; manufactured by Taiyo Chemical Co., Ltd.) A small amount of vitamins / minerals and powdered flavor were added and mixed uniformly to obtain about 380 g of an oral liquid food containing the composition A for improving blood flow. Furthermore, in place of the composition A for improving blood flow, instead of using the compositions B to D for improving blood flow, a composition-containing oral liquid food for improving blood flow was obtained.

[Example 8] Preparation of tablet containing composition for improving blood flow A, 1 g of composition A for improving blood flow obtained in Example 1, 5 g of crystalline cellulose, 13.8 g of corn starch, 32.5 g of lactose, hydroxypropylcellulose 3.3 g was mixed and granulated. To this granulated product, 1.0 g of magnesium stearate is added, mixed uniformly, and this mixture is pressure-molded with a rotary tableting machine, whereby one tablet contains 130 mg of the composition for improving blood flow of the present invention. Got. Furthermore, instead of the composition A for improving blood flow, tablets containing the composition for improving blood flow were obtained in the same manner except that the compositions B to D for improving blood flow were used.

[Example 9] Preparation of drink containing composition for improving blood flow Into 5.5 g of composition A for improving blood flow obtained in Example 1, 528 g of glucose, 85.4 g of fructose, and 15.8 g of powdered citric acid 11.2 g of sodium citrate, 1.3 g of calcium lactate, 1.3 g of magnesium chloride, 13.2 g of powdered natural flavor, vitamin C were added, and water was added to make 11 liters. This liquid was filled in a dry heat sterilized 110 ml brown bottle, sealed with an aluminum cap, and then sterilized at 120 ° C. for 30 minutes to obtain 100 drinks. Furthermore, a composition-containing drink for improving blood flow was obtained in the same manner except that the blood flow improving compositions B to D were used instead of the blood flow improving composition A.

Example 10 Preparation of Capsules Containing Composition for Improvement of Blood Flow After adding 50 g of composition A for improving blood flow obtained in Example 1 to 1 g of copper chlorophyllate and heat sterilizing it, The pharmacy capsule (# 1) was filled with 0.4 g per capsule to obtain 100 capsules. Furthermore, a composition-containing capsule for improving blood flow was obtained in the same manner except that the blood flow improving compositions B to D were used instead of the blood flow improving composition A.

Example 11 Preparation of Pig Breeding Feed Containing Composition for Improvement of Blood Flow 40.5 parts by weight of corn and 28 of Milo against 0.5 part by weight of Composition B for improvement of blood flow obtained in Example 1 0.0 parts by weight, soybean oil residue 11.0 parts, bran 6.0 parts by weight, fish meal 5.0 parts by weight, animal fats and oils 2.0 parts by weight, vitamins and minerals 3.0 parts by weight Then, 20 kg of pig breeding feed was prepared. Furthermore, the composition for blood flow improvement containing pig breeding feed was obtained in the same manner except that the blood flow improvement compositions B to D were used instead of the blood flow improvement composition A.

Examples of the present invention and the target product are as follows.
(1) A composition for improving blood flow, comprising as an active ingredient at least one selected from the group consisting of elaeocalpsin, keblagic acid, geraniin and corilagin.
(2) The composition for improving blood flow according to the above (1), wherein the active ingredients elaeocalpsin, keblagic acid, geraniin and corilagin are extracted from natural plants.
(3) The composition for improving blood flow according to the above (1), wherein the active ingredients elaeocalpsin, keblagic acid, geraniin and corilagin are extracted from Amler.
(4) A fraction obtained by purifying a product obtained by treating and decomposing a plant with at least one enzyme selected from the group consisting of pectinase, protease, tannase and cellulase in (2) or (3) As a composition for improving blood flow.
(5) A food or drink comprising the composition for improving blood flow according to any one of (1) to (4) above.
(6) A feed comprising the composition for improving blood flow according to any one of (1) to (4) above.
(7) A quasi-drug containing the composition for improving blood flow according to any one of (1) to (4) above.
(8) A pharmaceutical comprising the composition for improving blood flow according to any one of (1) to (4) above.
(9) A blood flow improving method for improving blood fluidity using the blood flow improving composition according to any one of (1) to (4).
(10) A blood flow improving method for improving blood fluidity in vivo using the blood flow improving composition according to any one of (1) to (4) above.
(11) A method for improving blood flow, which allows a living body to ingest the composition for improving blood flow according to any one of (1) to (4) above and improves blood fluidity in the living body.
(12) The method for improving blood flow according to (11), wherein the organism is an organism excluding a human being.

Claims (6)

For improving blood flow, comprising as an active ingredient at least one selected from the group consisting of Elaeocarpusin, Keblagic acid, Geraniin, and Corilagin Composition. The composition for improving blood flow according to claim 1, wherein the active ingredients elaeocalpsin, keblagic acid, geraniin and corilagin are extracted from natural plants. A food or drink comprising the composition for improving blood flow according to claim 1 or 2. A feed comprising the composition for improving blood flow according to claim 1 or 2. A quasi-drug containing the composition for improving blood flow according to claim 1 or 2. A pharmaceutical comprising the composition for improving blood flow according to claim 1 or 2.